Pharmamarketeer

EMA committee recommends approval of GSK’s IV Benlysta in children with lupus aged five years and above

GSK announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending the use of intravenous (IV) Benlysta (belimumab)

Medhc-fases-banner
Advertentie(s)